Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, which continues to benefit more patients with cancer globally, the successful launch of WINREVAIR and strong performance of our Animal Health business,” said Robert M. Davis, chairman and chief executive officer, Merck (MRK). “We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development. Our business remains well positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Notable companies reporting before tomorrow’s open
- MRK Upcoming Earnings Report: What to Expect?
- Merck’s capvaxive receives positive EU CHMP opinion for pneumococcal vaccine
- Kennedy says he will give away rights to fees from vaccine litigation, NYT says
- NVS Earnings: Entresto Drugmaker Novartis Tops Estimates as Patent Expiry Looms